ARD-103 / ARCE Therapeutics - LARVOL DELTA

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS (clinicaltrials.gov) - P1/2 | N=49 | Recruiting | Sponsor: ARCE Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies (clinicaltrials.gov) - P=N/A | N=49 | Not yet recruiting | Sponsor: ARCE Therapeutics, Inc.

New trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology